Unknown (formerly Psychedelics Development; now potentially AI/Robotics Wellness)
Strategic Profile
Historical profile (2021-2022): Mycotopia was a psychedelics-focused biopharma company pursuing natural and biosynthetic psilocybin development, supply agreements with Havn Life Sciences, and planned mergers with Ei.Ventures. However, this profile is obsolete due to corporate restructuring.
Cyborg Score Rationale
Cannot assess current company viability, strategy, or competitive position without current 2026 operational data. Corporate identity appears to have changed materially.
Top Insights
Corporate transition from Mycotopia Therapies (psychedelics) to AIBiotics (AI/robotics/wellness) occurred post-2022
Historical supply agreement with Havn Life Sciences for naturally-derived psilocybin (2021)
Historical biosynthetic subsidiary PsyBioMed aimed for 70-90% cost reduction in psilocybin production
No verifiable current operational data available for June 2026
Recent Developments
(May 2022) Strategic investments in Avicanna Inc. and planned public merger with Ei.Ventures
(2022) Corporate restructuring initiated; transition to AIBiotics announced
(June 2026) Current status unknown—no recent press releases or SEC filings located
Open the full interactive Mycotopia Therapies, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.